CliffBio
small molecule

ERYTHROMYCIN ESTOLATE

ERYTHROMYCIN ESTOLATE

Loss of exclusivity—loss of exclusivity
CompanyCosette Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameERYTHROMYCIN ESTOLATE
Active ingredientERYTHROMYCIN ESTOLATE
StrengthEQ 125MG BASE/5ML
Dosage formSUSPENSION
RouteORAL
ModalitySmall molecule
FDA approvalOctober 1990
Marketing statusDISCN

More from Cosette Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.